6533b7dcfe1ef96bd127218e

RESEARCH PRODUCT

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Martin GramatzkiBernd MetznerFriederike BachmannChristian StrakaAnnamaria BrioliMax BittrichMartin SchrederSwantje HeldHermann EinseleHans SalwenderTobias DechowChristoph RölligKai-uwe EckardtSebastian TheurichMatthias GrubeDenise WolleschakMonika EngelhardtKerstin Schäfer-eckartHolger HebartBernd HertensteinLeo RascheIgor Wolfgang BlauStefan KnopGeorg MaschmeyerWolfram JungCyrus KhandanpourLars Olof MüggeChristian LangerPeter LiebischFlorian BassermannIvana Von MetzlerHeinz DürkGeorg Hess

subject

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drug

description

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

yearjournalcountryeditionlanguage
2021-03-16Cancers
https://doi.org/10.3390/cancers13061322